{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:00:57Z","timestamp":1794265257142,"version":"4.9.0"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014935","name":"BioCryst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The complement system is central to first-line defense against invading pathogens. However, excessive complement activation and\/or the loss of complement regulation contributes to the development of autoimmune diseases, systemic inflammation, and thrombosis. One of the three pathways of the complement system, the alternative complement pathway, plays a vital role in amplifying complement activation and pathway signaling. Complement factor D, a serine protease of this pathway that is required for the formation of C3 convertase, is the rate-limiting enzyme. In this review, we discuss the function of factor D within the alternative pathway and its implication in both healthy physiology and disease. Because the alternative pathway has a role in many diseases that are characterized by excessive or poorly mediated complement activation, this pathway is an enticing target for effective therapeutic intervention. Nonetheless, although the underlying disease mechanisms of many of these complement-driven diseases are quite well understood, some of the diseases have limited treatment options or no approved treatments at all. Therefore, in this review we explore factor D as a strategic target for advancing therapeutic control of pathological complement activation.<\/jats:p>","DOI":"10.3389\/fimmu.2021.712572","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T05:35:13Z","timestamp":1631165713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":129,"title":["Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway"],"prefix":"10.3389","volume":"12","author":[{"given":"Jonathan","family":"Barratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and Its Role in Innate and Adaptive Immune Responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The Renaissance of Complement Therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement System Part I \u2013 Molecular Mechanisms of Activation and Regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001392","article-title":"The Pathophysiology of Geographic Atrophy Secondary to Age-Related Macular Degeneration and the Complement Pathway as a Therapeutic Target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The Alternative Complement Pathway Revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406849111","article-title":"Complement Activation by Ligand-Driven Juxtaposition of Discrete Pattern Recognition Complexes","volume":"111","author":"Degn","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1983.tb18116.x","article-title":"Initiation of the Alternative Complement Pathway Due to Spontaneous Hydrolysis of the Thioester of C3","volume":"421","author":"Pangburn","year":"1983","journal-title":"Ann NY Acad Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0090-1229(90)90043-p","article-title":"C5a-Mediated Release of Interleukin 6 by Human Monocytes","volume":"57","author":"Scholz","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.12.002","article-title":"Expression of Anaphylatoxin Receptors on Platelets in Patients With Coronary Heart Disease","volume":"238","author":"Patzelt","year":"2015","journal-title":"Atherosclerosis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019.00131","article-title":"Platelets and Complement Cross-Talk in Early Atherogenesis","volume":"6","author":"Kim","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41423-018-0024-0","article-title":"NETosis, Complement, and Coagulation: A Triangular Relationship","volume":"16","author":"de Bont","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B13","first-page":"1","article-title":"Human Protectin (CD59), an 18,000-20,000 MW Complement Lysis Restricting Factor, Inhibits C5b-8 Catalysed Insertion of C9 Into Lipid Bilayers","volume":"71","author":"Meri","year":"1990","journal-title":"Immunology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.142.4.856","article-title":"Properdin: Binding to C3b and Stabilization of the C3b-Dependent C3 Convertase","volume":"142","author":"Fearon","year":"1975","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The Quantitative Role of Alternative Pathway Amplification in Classical Pathway Induced Terminal Complement Activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.148.6.1498","article-title":"Mechanism of Action of Factor D of the Alternative Complement Pathway","volume":"148","author":"Lesavre","year":"1978","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5560050401","article-title":"Complement Factor D, A Novel Serine Protease","volume":"5","author":"Volanakis","year":"1996","journal-title":"Protein Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)50409-4","article-title":"Human Adipsin Is Identical to Complement Factor D and Is Expressed at High Levels in Adipose Tissue","volume":"267","author":"White","year":"1992","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42338-1","article-title":"Adipsin and an Endogenous Pathway of Complement From Adipose Cells","volume":"267","author":"Choy","year":"1992","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0610-4","article-title":"Adipsin Preserves Beta Cells in Diabetic Mice and Associates With Protection From Type 2 Diabetes in Humans","volume":"25","author":"G\u00f3mez-Banoy","year":"2019","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI12023","article-title":"A Family With Complement Factor D Deficiency","volume":"108","author":"Biesma","year":"2001","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114384","article-title":"Complete and Partial Deficiencies of Complement Factor D in a Dutch Family","volume":"84","author":"Hiemstra","year":"1989","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112434","article-title":"Human Complement Protein D Catabolism by the Rat Kidney","volume":"77","author":"Sanders","year":"1986","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.214","article-title":"Metabolism of Complement Factor D in Renal Failure","volume":"34","author":"Pascual","year":"1988","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198502143120702","article-title":"Renal Filtration and Catabolism of Complement Protein D","volume":"312","author":"Volanakis","year":"1985","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1994.1064","article-title":"Preliminary Crystallographic Studies on Human Complement Pro-Factor D","volume":"235","author":"Narayana","year":"1994","journal-title":"J Mol Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7933","article-title":"Complement Factor D in Age-Related Macular Degeneration","volume":"52","author":"Stanton","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/srep31877","article-title":"MASP-3 Is the Exclusive Pro-Factor D Activator in Resting Blood: The Lectin and the Alternative Complement Pathways Are Fundamentally Linked","volume":"6","author":"Dob\u00f3","year":"2016","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700518","article-title":"Analysis of Factor D Isoforms in Malpuech\u2013Michels\u2013Mingarelli\u2013Carnevale Patients Highlights the Role of MASP-3 as a Maturase in the Alternative Pathway of Complement","volume":"199","author":"Pihl","year":"2017","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/bi982140f","article-title":"Induced Fit Activation Mechanism of the Exceptionally Specific Serine Protease, Complement Factor D","volume":"38","author":"Taylor","year":"1999","journal-title":"Biochemistry"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.4.804","article-title":"Structural Basis of Profactor D Activation: From a Highly Flexible Zymogen to a Novel Self-Inhibited Serine Protease, Complement Factor D","volume":"18","author":"Jing","year":"1999","journal-title":"EMBO J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1998.2089","article-title":"Structures of Native and Complexed Complement Factor D: Implications of the Atypical His57 Conformation and Self-Inhibitory Loop in the Regulation of Specific Serine Protease Activity","volume":"282","author":"Jing","year":"1998","journal-title":"J Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1107\/S1399004713032549","article-title":"Ensemble Refinement Shows Conformational Flexibility in Crystal Structures of Human Complement Factor D","volume":"70","author":"Forneris","year":"2014","journal-title":"Acta Crystallogr D. Biol Crystallogr"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(18)61371-7","article-title":"Human Complement Proteins D, C2 and B. Active Site Mapping With Peptide Thioester Substrates","volume":"262","author":"Kam","year":"1987","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molimm.2014.10.017","article-title":"Alternative Complement Pathway Component Factor D Contributes to Efficient Clearance of Tissue Debris Following Acute CCl4-Induced Injury","volume":"64","author":"Cresci","year":"2015","journal-title":"Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00334.2017","article-title":"Complement Factor D Protects Mice From Ethanol-Induced Inflammation and Liver Injury","volume":"315","author":"McCullough","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00537.2010","article-title":"Innate Immunity in Alcoholic Liver Disease","volume":"300","author":"Gao","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1512","article-title":"Senescent Dermal Fibroblasts Negatively Influence Fibroblast Extracellular Matrix-Related Gene Expression Partly via Secretion of Complement Factor D","volume":"45","author":"Ezure","year":"2019","journal-title":"Biofactors"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.20.9363","article-title":"A Biomarker That Identifies Senescent Human Cells in Culture and in Aging Skin In Vivo","volume":"92","author":"Dimri","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0162228","DOI":"10.1371\/journal.pone.0162228","article-title":"Small Molecule-Induced Complement Factor D (Adipsin) Promotes Lipid Accumulation and Adipocyte Differentiation","volume":"11","author":"Song","year":"2016","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev.pathol.2.010506.091859","article-title":"Endocrine Functions of Adipose Tissue","volume":"2","author":"Waki","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","article-title":"Adipsin is an Adipokine That Improves \u03b2 Cell Function in Diabetes","volume":"158","author":"Lo","year":"2014","journal-title":"Cell"},{"key":"B43","article-title":"Functional Deficiency of Complement Factor D in a Monozygous Twin","volume":"58","author":"Kluin-Nelemans","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02918259","article-title":"Complement Deficiency States and Meningococcal Disease","volume":"12","author":"Figueroa","year":"1993","journal-title":"Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2820","article-title":"Deficient Alternative Complement Pathway Activation Due to Factor D Deficiency by 2 Novel Mutations in the Complement Factor D Gene in a Family With Meningococcal Infections","volume":"107","author":"Sprong","year":"2006","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e007818","DOI":"10.1161\/JAHA.117.007818","article-title":"Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease","volume":"7","author":"Jalal","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.celrep.2019.05.032","article-title":"Fat-Produced Adipsin Regulates Inflammatory Arthritis","volume":"27","author":"Li","year":"2019","journal-title":"Cell Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.3.647","article-title":"The Excessive Complement Activation in Fulminant Meningococcal Septicemia Is Predominantly Caused by Alternative Pathway Activation","volume":"173","author":"Brandtzaeg","year":"1996","journal-title":"J Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The Spectrum of Renal Thrombotic Microangiopathy in Lupus Nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1342","article-title":"Complement-Targeted Therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00271","article-title":"Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway","volume":"62","author":"Karki","year":"2019","journal-title":"J Med Chem"},{"key":"B52","first-page":"3","article-title":"Paroxysmal Nocturnal Haemoglobinuria: Clinical Manifestations, Haematology, and Nature of the Disease","volume":"5","author":"Dacie","year":"1972","journal-title":"Ser Haematol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","article-title":"Diseases of Complement Dysregulation\u2014An Overview","volume":"40","author":"Wong","year":"2018","journal-title":"Semin Immunopathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06240.x","article-title":"Paroxysmal Nocturnal Haemoglobinuria (PNH) Is Caused by Somatic Mutations in the PIG-A Gene","volume":"13","author":"Bessler","year":"1994","journal-title":"EMBO J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-Complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13166","article-title":"Diagnosis and Management of PNH: Review and Recommendations From a Belgian Expert Panel","volume":"101","author":"Devos","year":"2018","journal-title":"Eur J Haematol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1725468","article-title":"Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","volume":"20","author":"Lee","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: First Approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101331","article-title":"Complement Dysregulation in Glomerulonephritis","volume":"45","author":"Kaartinen","year":"2019","journal-title":"Semin Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 Glomerulopathy \u2014 Understanding a Rare Complement-Driven Renal Disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01820214","article-title":"Defining the Complement Biomarker Profile of C3 Glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B62","unstructured":"A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"},{"key":"B63","unstructured":"OL Extension Study of LNP023 in C3G"},{"key":"B64","unstructured":"Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)"},{"key":"B65","unstructured":"Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (ACCOLADE)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000490201","article-title":"Thrombomodulin and Endothelial Dysfunction: A Disease-Modifier Shared Between Malignant Hypertension and Atypical Hemolytic Uremic Syndrome","volume":"140","author":"Demeulenaere","year":"2018","journal-title":"Nephron"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin Mutations in Atypical Hemolytic-Uremic Syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16651","article-title":"Mutations in Factor H Reduce Binding Affinity to C3b and Heparin and Surface Attachment to Endothelial Cells in Hemolytic Uremic Syndrome","volume":"111","author":"Manuelian","year":"2003","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7532507","article-title":"Complement System and Age-Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine","volume":"2018","author":"Maugeri","year":"2018","journal-title":"BioMed Res Int"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-60","article-title":"ANCA-Associated Vasculitis","volume":"17","author":"Yates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1159\/000442323","article-title":"Overview of the Pathogenesis of ANCA-Associated Vasculitis","volume":"1","author":"Xiao","year":"2016","journal-title":"Kidney Dis (Basel)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02166","article-title":"Complement Inhibitors in Clinical Trials for Glomerular Diseases","volume":"10","author":"Zipfel","year":"2019","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102424","article-title":"Complement Alternative Pathway in ANCA-Associated Vasculitis: Two Decades From Bench to Bedside","volume":"19","author":"Brilland","year":"2020","journal-title":"Autoimmun. Rev"},{"key":"B74","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.13498","article-title":"The Alternative Complement Pathway in ANCA-Associated Vasculitis: Further Evidence and a Meta-Analysis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.06.018","article-title":"ANCA Associated Vasculitis: The Journey to Complement-Targeted Therapies","volume":"112","author":"Quintana","year":"2019","journal-title":"Mol Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.018","article-title":"Targeting the Complement Cascade: Novel Treatments Coming Down the Pike","volume":"90","author":"Thurman","year":"2016","journal-title":"Kidney Int"},{"key":"B78","unstructured":"A Study to Evaluate the Effectiveness and Safety of IONIS-FB\u2013LRX, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00504","article-title":"The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2633004020959349","article-title":"A Review of the Treatment Landscape in Paroxysmal Nocturnal Haemoglobinuria: Where Are We Now and Where Are We Going","volume":"1","author":"Griffin","year":"2020","journal-title":"Ther Adv Rare Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A Review in Generalized Myasthenia Gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071693","article-title":"Therapeutic Approaches With Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules","volume":"20","author":"Nebbioso","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan Versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N. Engl J Med"},{"key":"B85","unstructured":"Empaveli: Powerful New Drug for Paroxysmal Nocturnal Hemoglobinuria"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic Variants in C5 and Poor Response to Eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116","article-title":"Small-Molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B88","unstructured":"Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.153312","article-title":"Small-Molecule Factor D Inhibitors Selectively Block the Alternative Pathway of Complement in Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome","volume":"102","author":"Yuan","year":"2017","journal-title":"Haematologica"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2208","article-title":"Small-Molecule Factor D Inhibitors Targeting the Alternative Complement Pathway","volume":"12","author":"Maibaum","year":"2016","journal-title":"Nat Chem Biol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0655-8","article-title":"Expanding Horizons in Complement Drug Discovery: Challenges and Emerging Strategies","volume":"40","author":"Harris","year":"2018","journal-title":"Semin Immunopathol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000484257","article-title":"Kallikrein Cleaves C3 and Activates Complement","volume":"10","author":"Irmscher","year":"2018","journal-title":"J Innate Immun"},{"key":"B93","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in Disease: A Defence System Turning Offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701668","article-title":"Contribution of Adipose-Derived Factor D\/adipsin to Complement Alternative Pathway Activation: Lessons From Lipodystrophy","volume":"200","author":"Wu","year":"2018","journal-title":"J Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00425","article-title":"Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition In Vivo","volume":"60","author":"Lorthiois","year":"2017","journal-title":"J Med Chem"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00299","article-title":"Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors","volume":"7","author":"Yang","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.345082","article-title":"Inhibiting Alternative Pathway Complement Activation by Targeting the Factor D Exosite","volume":"287","author":"Katschke","year":"2012","journal-title":"J Biol Chem"},{"key":"B98","unstructured":"Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)"},{"key":"B99","unstructured":"A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab (PNH)"},{"key":"B100","unstructured":"A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)"},{"key":"B101","unstructured":"A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)"},{"key":"B102","unstructured":"A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G)"},{"key":"B103","unstructured":"A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN"},{"key":"B104","unstructured":"Study of the Metabolism of Danicopan in Healthy Adults"},{"key":"B105","unstructured":"A Study of the Effects of Food and Age on Danicopan"},{"key":"B106","unstructured":"A Drug Interaction Study of Danicopan"},{"key":"B107","unstructured":"Study of Danicopan in Participants of Japanese Descent"},{"key":"B108","unstructured":"Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH)"},{"key":"B109","unstructured":"Study of Radiolabeled ALXN2050 in Healthy Adult Males"},{"key":"B110","unstructured":"A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-in-Capsule in Healthy Adult Participants"},{"key":"B111","unstructured":"A Drug Interaction Study of ACH-0145228"},{"key":"B112","unstructured":"A Study of the Cardiac Effects of ALXN2050 in Healthy Adults"},{"key":"B113","unstructured":"Study of ALXN2050 in Participants With Renal Impairment"},{"key":"B114","unstructured":"A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)"},{"key":"B115","unstructured":"First-In-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261826","article-title":"Danicopan: An Oral Complement Factor D Inhibitor for Paroxysmal Nocturnal Hemoglobinuria","author":"Risitano","year":"2020","journal-title":"Haematologica"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011388","article-title":"Phase 2 Study of Danicopan in Paroxysmal Nocturnal Hemoglobinuria Patients With an Inadequate Response to Eculizumab","author":"Kulesekararaj","year":"2021","journal-title":"Blood"},{"key":"B118","article-title":"BCX9930, an Oral Factor D Inhibitor, for the Potential Treatment of Alternative Pathway Mediated Diseases: Interim Results of a Phase 1 Study in Healthy Subjects","volume-title":"Blood","author":"Davidson","year":"2020"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138838","article-title":"BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept as Monotherapy in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","volume":"136","author":"Kulasekararaj","year":"2020","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"eaaf1443","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting Factor D of the Alternative Complement Pathway Reduces Geographic Atrophy Progression Secondary to Age-Related Macular Degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Sci Transl Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of Neuromyelitis Optica: State-of-the-Art and Emerging Therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304","article-title":"IgG Marker of Optic-Spinal Multiple Sclerosis Binds to the Aquaporin-4 Water Channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12132","article-title":"Increased Soluble C5b-9 in CSF of Neuromyelitis Optica","volume":"79","author":"Wang","year":"2014","journal-title":"Scand J Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008248","article-title":"Direct Activation of the Alternative Complement Pathway by SARS-CoV-2 Spike Proteins Is Blocked by Factor D Inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement Associated Microvascular Injury and Thrombosis in the Pathogenesis of Severe COVID-19 Infection: A Report of Five Cases","volume":"220","author":"Magro","year":"2020","journal-title":"Transl Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8422-y","article-title":"Complement and Autoimmunity","volume":"56","author":"Ballanti","year":"2013","journal-title":"Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.712572\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T05:35:31Z","timestamp":1631165731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.712572\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":127,"alternative-id":["10.3389\/fimmu.2021.712572"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.712572","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"article-number":"712572"}}